[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-tumors":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,49,71,97,126,159,198,224,251,281,311,344,367],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100614038","assessment-of-early-post-operative-nuclear-imaging-in-neurosurgery-a-safety-and-feasibility-study-in-patients-operated-for-glioblastoma-100614038",false,"NCT07274397","Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma","EARLYBRAINPET","Inclusion Criteria:\n\n* First resection for a suspected glioblastoma in the past 72h\n* Signed informed consent\n\nnon-inclusion Criteria:\n\n* Deprived of liberty or under legal protection (e.g, guardianship, trusteeship)\n* Patients under 18 years old\n* Absence of social security cover\n* Pregnancy\n* Emergency procedure\n* Contraindication to brain MRI, including claustrophobia\n* Contraindication to radiotracers or gadolinium injection\n* Preoperative cognitive impairment impeding patient information\n\nExclusion criteria :\n\n* Any postoperative behavioral disorders or medical condition or symptom impeding the completion of brain imaging\n* Postoperative medical dependency impeding the patient transfer to the nuclear medicine department (including, but not limited to, invasive ventilation, need for external ventricular drainage…)\n* Postoperative histological diagnosis different from glioblastoma","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23],"NA","This clinical trial aims to evaluate the feasibility and safety of early post-operative brain PET-MRI imaging in adult patients who have undergone surgery for suspected glioblastoma. The study also seeks to validate specific nuclear imaging parameters for better detection of residual tumor tissue compared to standard gadolinium-enhanced MRI. The main objectives are to determine whether early PET-MRI within 48 hours post-surgery is feasible, to assess potential side effects related to imaging procedures, and to explore if PET parameters such as SUVmax, metabolic volume, and tumor-to-striatum ratio can improve the detection of tumor residue. A total of 15 patients will be included at a single site in France. Participants will undergo PET-MRI using 18F-DOPA and gadolinium, and will be monitored for radiation exposure and possible adverse events up to 24 hours after imaging.",[26,27,28],"Glioblastoma","Brain Tumors","Brain Imaging",[26,30,31,32,33,34,35],"brain tumors","PET-MRI","18F-DOPA","Radiotracer","Diagnostic Imaging","Nuclear Medicine","RECRUITING","2026-06-05",{"date":39,"type":40},"2026-06-08","ACTUAL",{"date":42,"type":40},"2026-04-17",{"date":44,"type":20},"2027-04-17",{"name":46,"class":47},"Beta Emitting Accurate Monitored Systems","INDUSTRY",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":48},"100639826","spectral-precise-image-study-for-brain-tumors-100639826","NCT07620470","Spectral Precise Image Study for Brain Tumors","Clinical Study for Exploring Image Quality the Spectral Precise Image in Patients With Diagnosed Intracranial Tumors","Inclusion Criteria:\n\n1. Patients with clinical and radiology (MRI\u002FCT) diagnosed brain tumors.\n2. Patients who underwent contrast enhanced scans using the Spectral CT 7500.\n3. Study participants with age ≥ 18 years old.\n4. Study participants that have signed Informed Consent Form (ICF)\n\nExclusion Criteria:\n\n1. The clinical data or radiological information is considered incomplete after evaluation by the investigator.\n2. Study participant that was enrolled in this study in the past\n3. Data from study participants deemed unsuitable for enrollment based on the investigator's evaluation",true,{"count":58,"type":20},120,"OBSERVATIONAL","The goal of this observational study is to explore the image quality of spectral CT deep learning reconstruction technology (Spectral Precise Image) of patients with confirmed brain tumors.\n\nThe main question it aims to answer is:\n\nThe Image Quality (IQ) and diagnostic confidence of Spectral Precise Image reconstructions",[27],"2026-05-27",{"date":64,"type":40},"2026-06-02",{"date":66,"type":40},"2025-11-28",{"date":68,"type":20},"2026-12-31",{"name":70,"class":47},"Philips Clinical & Medical Affairs Global",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":94,"locationsCount":4},"100637710","diagnostic-performance-and-quantitative-analysis-of-18ffet-pet-in-brain-tumours-100637710","NCT07599917","Diagnostic Performance and Quantitative Analysis of [18F]FET PET in Brain Tumours","FET-BRAIN-DX","Inclusion Criteria:\n\n* Patients who underwent a brain PET\u002FCT or PET\u002FMRI scan with \\[18F\\]FET for clinical reasons during the study period.\n* Age ≥ 18 years.\n* Indication for the scan related to diagnosis, grading, assessment of treatment response or suspected recurrence of any brain tumour (primary or metastatic).\n* Availability of the corresponding static and dynamic images.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* . Pregnancy or breastfeeding",{"count":79,"type":20},69,"This is a retrospective study encompassing all \\[18F\\]FET PET scans performed at our centre. By analysing both static and dynamic scans, conducting in-depth kinetic modelling, and comparing quantitative parameters across different tumour types and clinical contexts, the study aims to determine the true diagnostic value of \\[18F\\]FET PET in everyday clinical practice. The ultimate goal is to identify imaging biomarkers useful for improving tumour characterisation and distinguishing recurrence from post-treatment changes, thereby strengthening the role of \\[18F\\]FET PET in modern neuro-oncology.",[27],[83,27,84,85,86],"FET PET","Meningioma","Diagnostic Accuracy","Dynamic PET Imaging","NOT_YET_RECRUITING","2026-05-14",{"date":90,"type":40},"2026-05-20",{"date":92,"type":20},"2026-06-01",{"date":68,"type":20},{"name":95,"class":96},"IRCCS San Raffaele","OTHER",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":108,"conditions":109,"keywords":115,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":48},"100578364","early-phase-1-pain-control-and-quality-of-recovery-after-intravenous-methadone-versus-intravenous-remifentanil-in-craniotomy-surgery-100578364","NCT06810336","Pain Control and Quality of Recovery After Intravenous Methadone Versus Intravenous Remifentanil in Craniotomy Surgery","Inclusion Criteria:\n\n1. Adult Patients between ages 18 and 65 years old.\n2. Undergoing supratentorial intracranial surgery\n3. American Society of Anesthesiologists (ASA) physiological status I-III\n4. Body Mass Index (BMI) between 18.5 and 45\n5. Ability to understand and read English\n\nExclusion Criteria:\n\n1. Being unable or unwilling to sign a consent\n2. Anticipated discharge within 24 hours after surgery\n3. Patients requiring Emergent Surgery\n4. Preoperative usage of Methadone, or allergy to it.\n5. Patients with chronic pain, requiring daily opioid use at the time of surgery, MME \\>60 as FDA defines opioid tolerant as 60 MME, long-acting forms of opioids such as fentanyl patch, oxycontin\n6. Active or Prior Substance Use Disorder, undergoing active treatment with Medication of Opioid Use Disorder including methadone (once daily dosing), Buprenorphine (any formulation) and Naltrexone\n7. Preoperative chronic renal insufficiency or failure (defined as a serum creatinine more than 2 mg\u002Fdl),\n8. Pregnancy\n9. Significant liver disease (cirrhosis or hepatic failure)\n10. QTc \\>450 on preoperative electrocardiogram\n11. Pulmonary disease necessitating home oxygen therapy\n12. Inability to speak or read the English language","65 Years",{"count":105,"type":20},40,[107],"EARLY_PHASE1","Postoperative pain is prevalent after intracranial surgery. Patients undergoing craniotomy are typically managed with short acting opioids to enable early and reliable post-operative neurological exam as well as avoid the risk of respiratory depression. However, a plethora of studies have shown that a majority of these patients experience moderate to severe pain in first 48 hours after surgery. Suboptimal pain control can lead to complications such as arterial hypertension and post-operative intracranial hemorrhage, and hence, increased morbidity and mortality.\n\nIntravenous (IV) methadone has a long analgesic half-life and has N-methyl-D-aspartate (NMDA) receptor antagonist and serotonin and norepinephrine reuptake inhibitor (SNRI) properties. It has previously been shown to reduce postoperative opioid requirements, postoperative nausea and vomiting (PONV), and postoperative pain scores in patients that underwent orthopedic, abdominal, complex spine, and cardiac surgery. Similar findings have been shown in obstetric patients that underwent caesarean delivery under general anesthesia as well as patients that underwent gynecologic surgery and received IV methadone intraoperatively.\n\nIn a recently published retrospective study, a single intraoperative dose of IV methadone was well tolerated with lower pain scores as well as MME (oral morphine milligram equivalents) requirements for up to 72 hours after elective intracranial surgery.\n\nIV methadone has, however, never been compared with conventional management via IV remifentanil for functional recovery in patients undergoing elective intercranial surgery.\n\nThe investigator's hypothesis is that intravenous (IV) methadone is non-inferior to IV remifentanil in patients who undergo elective intracranial surgery. It offers the advantage of being a single dose noninvasive analgesic modality that may contribute to decreasing MME consumption during the first 72 hours postoperatively, controlling postoperative pain, and improving quality of recovery after surgery.",[110,27,111,112,113,114],"Brain Injury","Craniotomy Surgery","Pain","Postoperative","Postoperative Care",[116],"craniotomy","2026-04-27",{"date":119,"type":40},"2026-05-04",{"date":121,"type":40},"2025-03-10",{"date":123,"type":20},"2027-09-10",{"name":125,"class":96},"University of Virginia",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":133,"maxAge":103,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":137,"conditions":138,"keywords":142,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":48},"100633734","rtms-for-postoperative-brain-tumor-patients-100633734","NCT07530536","rTMS for Postoperative Brain Tumor Patients","Repetitive Transcranial Magnetic Stimulation for Enhancing Motor Recovery in Postoperative Brain Tumor Patients","Inclusion Criteria:\n\n1. Patients aged 22-65 years old who have undergone surgical resection for a brain tumor.\n2. Patients undergoing any form of prior therapy, other than previous TMS therapy, will be considered.\n3. Patients who present with sustained postoperative motor deficits at 1-2 weeks postoperatively as defined by the presence of British Medical Research Council (MRC) motor scores of 3\u002F5 or less, or a sustained decrement by one point on the MRC score in the affected extremity.\n4. Patients who present within three years of surgery with chronic, persistent motor-functional deficits will be included to demonstrate generalizability of safety and efficacy in neurosurgery patients with chronic deficits.\n5. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patients with any clinical history of seizures.\n2. Patients with implanted devices (e.g., pacemakers, implanted stimulators, intracranial electrodes, cochlear implants).\n3. Patients who have undergone a brain biopsy alone without resection.\n4. Patients with postoperative cognitive deficits as defined by a Mini Mental State Examination score \\\u003C26.\n5. History of bipolar disorder.\n6. Pregnant or breast-feeding individuals.\n7. Active suicidal ideation or plan as assessed by the Columbia Suicide Severity Rating Scale.\n8. History of moderate to severe heart disease.\n9. History of other neurological conditions defined by structural cerebral damage (e.g., stroke, multiple sclerosis, other neurodegenerative diseases, meningoencephalitis)","22 Years",{"count":135,"type":20},6,[23],"When doctors perform surgery to remove brain tumors, the goal is to take out as much of the tumor as possible while keeping the patient's brain functions intact. However, sometimes patients have trouble with movements like walking or using their hands after surgery. One reason for this is unintentional damage to important areas of the brain during the operation. A technique called Transcranial Magnetic Stimulation (TMS) might help patients recover these lost abilities faster.\n\nThe investigators are conducting a study to see if TMS can help patients recover their movement abilities after brain tumor surgery. TMS uses magnetic pulses to stimulate specific parts of the brain. In this study, the investigators will treat six patients with TMS once per day for three days in a row. Three patients with recent movement difficulties one to two weeks after surgery will be recruited for this study; they will also receive physical therapy. An additional three patients with persisting movement difficulties up to three years after tumor surgery will also be recruited for this study, regardless of whether or not they receive physical therapy.\n\nThe investigators will use two standard tests to see how well patients can move before and after the TMS treatment. These tests will help the investigators understand if TMS is making a difference in their recovery.",[27,139,140,141],"Transcranial Magnetic Stimulation","Motor Deficit","Quality of Life",[143,144,145,146,147,148,149],"Transcranial magnetic stimulation","Brain tumor","Post-operative muscle weakness","Quality of life","Brain tumor surgery","TMS","Post-craniotomy","2026-04-10",{"date":152,"type":40},"2026-04-15",{"date":154,"type":20},"2026-06",{"date":156,"type":20},"2028-04",{"name":158,"class":96},"Brian J.Gill",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100583603","simplification-of-care-pathways-for-patients-with-rare-brain-tumors-through-artificial-intelligence-100583603","NCT06878469","SIMPLIFication of Care Pathways for Patients With Rare Brain Tumors Through Artificial Intelligence","SIMPLIF-AI: SIMPLIFication and Standardization of Care Pathways for Patients With Rare Brain Tumors Through Artificial Intelligence","SIMPLIF-AI","Inclusion Criteria:\n\n* Adults (age ≥18 years)\n* Both sexes\n* Patients with rare brain tumors (incidence \\\u003C6 cases per 100,000 people\u002Fyear)\n* Candidates for craniotomy for rare brain tumors\n* Native Italian speakers for cognitive and psychological evaluation and neuro-cognitive rehabilitation\n\nExclusion Criteria:\n\n* Patients undergoing stereotactic\u002Fframeless biopsy\n* Patients with psychiatric disorders or on psychotropic medications\n* Patients with known cognitive decline (not due to the lesion)\n* Patients admitted on the same day as the surgery\n* Patients with severe impairments referred to rehabilitation centers\n* Patients without a Windows PC or laptop with Internet connection for neuro-cognitive rehabilitation",{"count":168,"type":20},200,[23],"This study focuses on rare brain tumors, which are heterogeneous entities with different morphological, biological, and clinical characteristics. Due to their rarity, many of these tumors fall under the RARECARE definition of rare tumors. The main objective of the study is to standardize care models and pathways for patients with rare brain tumors, using Artificial Intelligence (AI) and Machine Learning (ML) techniques to identify specific predictors of postoperative outcomes.\n\nThe study includes both retrospective and prospective phases, with the collection of clinical, cognitive, and psychological data at various time points. Patients will undergo an early neuro-cognitive rehabilitation program using the RehaCom software, which will be conducted at home. The goal is to improve the quality of life and care for patients through a multidisciplinary and innovative approach.",[27],[173,174,175,176,177,178,179,180,181,182,183,184,185,186,187],"Rare brain tumors","neurosurgery","outcomes predictions","Machine Learning","Artificial Intelligence","neurocognitive rehabilitation","innovative models","health care pathways","Astrocytic tumors of CNS","Oligodendroglial tumors of CNS","Ependymal tumors of CNS","Neuronal and mixed neuronal-glial tumors","Choroid plexus carcinoma of CNS","Malignant meningiomas","Embryonal tumors of CNS","2026-02-17",{"date":190,"type":40},"2026-02-19",{"date":192,"type":40},"2025-01-27",{"date":194,"type":20},"2027-02",{"name":196,"class":96},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",2,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":21,"phases":208,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":197},"100550106","phase-3-short-versus-long-term-levetiracetam-in-brain-tumors-100550106","NCT06442748","Short Versus Long-term Levetiracetam in Brain Tumors","Short Versus Long-term Levetiracetam in Brain Tumors: A Phase 3 Randomized Controlled Trial (LIBRA)","LIBRA","Inclusion Criteria: • Age ≥ 18years\n\n* History of seizure\n* Histological diagnosis of primary brain tumor\n* Supratentorial location of primary tumor\n* Controlled on levetiracetam monotherapy for 6 months\n* Index surgery within 1 year\n* Karnofsky Performance Scale (KPS) ≥ 50\n\nExclusion Criteria:\n\n* KPS \\\u003C 50\n* No history of seizure\n* Unclear history of seizure episodes in the past\n* Use of antiepileptics other than levetiracetam in the previous 6 months\n* No histological diagnosis\n* Progressive disease\n* Brain metastasis\n* Altered mental status with deficits in understanding or inability to consent to the study",{"count":207,"type":20},604,[209],"PHASE3","Levetiracetam is the commonly preferred anti-seizure medicine in patients with brain tumors. This drug has reduced the risk of seizure events occurring but is associated with a risk of side effects such as increased headache, drowsiness, loss of muscle coordination, and psychological challenges in patients. In patients undergoing appropriate treatment for brain tumors and controlled of seizures in the initial few months of levetiracetam, the chance of further seizures is relatively low. The optimal duration to give levetiracetam is not well defined for these patients, and currently as standard treatment levetiracetam is continued for 2-3 years. This study aims to answer this question by comparing patients on a short course of levetiracetam (experimental arm) versus a longer course of levetiracetam (standard arm), with the anticipation that a shorter duration of treatment will not lead to increased seizure episodes.",[212,27,213,214],"Seizures","Antiepileptics","Levetiracetam","2026-02-11",{"date":217,"type":40},"2026-02-13",{"date":219,"type":40},"2024-07-04",{"date":221,"type":20},"2031-06-01",{"name":223,"class":96},"Tata Memorial Centre",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":48},"100118678","florida-center-for-brain-tumor-research-100118678","NCT00811148","Florida Center for Brain Tumor Research","Establishment of a UF Brain Tumor Tissue Bank: Florida Center for Brain Tumor Research","FCBTR","Inclusion Criteria:\n\n* Children and adults scheduled to undergo brain surgery to remove tumor tissue.",{"count":233,"type":20},4000,"The purpose of this research study is to collect and store brain tumor tissue samples for future research. The samples will become part of the University of Florida Brain Tumor Tissue Bank\u002FFlorida Center for Brain Tumor Research. The goal is to find improved treatments and cures for brain tumors.",[27],[237,238,239,240,241],"Brain Neoplasms","Central Nervous System Diseases","Central Nervous System Neoplasms","Brain Diseases","Nervous System Neoplasms","2026-01-09",{"date":244,"type":40},"2026-01-13",{"date":246,"type":4},"2006-03",{"date":248,"type":20},"2030-12",{"name":250,"class":96},"University of Florida",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":56,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":259,"conditions":260,"keywords":265,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":48},"100602692","a-vision-language-foundation-model-for-brain-disease-diagnosis-from-multimodal-data-100602692","NCT07126821","A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data","Inclusion Criteria:\n\nPatients with brain diseases:\n\n* Patients with brain tumors were pathologically diagnosed.\n* Patients with other brain diseases were correctly diagnosed.\n* The clinical case data of all patients were complete.\n\nNon-brain disease population:\n\n* All patients have complete clinical case data, complete brain MRI, no history brain diseases, no brain surgery or other brain diseases that affect the diagnosis and observation of MR imaging.\n\nExclusion Criteria:\n\n* Cases in which MRI were incomplete or with significant noise and artifacts.",{"count":258,"type":20},100000,"The goal of this observational study is to develop an innovative, comprehensive, and explainable AI vision-language foundation model (VLM) to advance the diagnosis and interpretation of brain diseases using multi-modal data. We will include patient demographics, medical imaging data (such as MRI, CT, and PET scans), histopathological data, genomic data when available, and other necessary laboratory examinations and tests to establish a screening and diagnostic model for brain diseases.",[261,262,263,27,240,264],"Brain (Nervous System) Cancers","Brain Arterial Disease","Neuro-Degenerative Disease","Neurological di",[30,266,267,268,269,270,271],"brain cancers","brain diseases","foundation model","diagnosis","prediction","neurological diseases","2025-08-15",{"date":274,"type":40},"2025-08-17",{"date":276,"type":40},"2025-05-15",{"date":278,"type":20},"2030-12-31",{"name":280,"class":96},"Xiangya Hospital of Central South University",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":16,"minAge":289,"maxAge":290,"enrollmentInfo":291,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":292,"conditions":293,"keywords":297,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":48},"100575992","systemic-biomarkers-to-predict-radiation-induced-neurocognitive-decline-100575992","NCT06779487","Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline","Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline in Pediatric and Young Adults With Primary Brain Tumors (BIO-RIN)","BIO-RIN","Inclusion Criteria:\n\n1. Age 5-39 years\n2. Histological diagnosis of primary brain tumor\n3. Decision for treatment with radical intent radiotherapy\n4. Signed assent and parental consent form for pediatric age group and signed consent form for adults.\n\nExclusion Criteria:\n\n1. Inability to undergo neurocognitive evaluation\n2. Palliative radiotherapy.\n3. Expected life expectancy \\\u003C 1 year","5 Years","39 Years",{"count":168,"type":20},"Radiation constitutes an integral component in the management of primary brain tumors in pediatric and young adults like medulloblastoma, ependymoma, low-grade glioma, pituitary tumors, etc. A decline in neurocognitive outcomes is a multifactorial effect occurring from the primary disease as well as associated with treatments, including radiation. Since many of these tumors are highly curable, it is crucial to reduce long-term side effects, including memory loss, to improve the quality of life in these patients, leading to better rehabilitation. Radiation-induced neurocognitive deterioration is postulated to occur from multiple factors like neuroinflammation, vascular damage, and depletion of neural stem cells. The proposed study will prospectively evaluate 200 pediatric and young adults with brain tumors treated with radiotherapy. Biological samples (peripheral blood and cerebrospinal fluid) will be procured during routine investigations (an additional amount will be collected for study purposes without the need for additional investigations). Serial blood markers (whenever available pre-operative and before, during, and after completion of radiation) of neuroinflammation and neural markers will be tested in patients undergoing radiation as part of their standard treatment, and correlate with the neurocognitive outcomes measured by age-appropriate Wechsler intelligence scales. Also, the impact of clinical (e.g. age) and radiotherapy parameters like volume, dose of radiation, and technique (photon versus proton therapy) on acute (during radiotherapy) and late systemic inflammatory markers will be analyzed. The study will even provide the opportunity to know the influence of radiation on systemic neuroinflammatory markers in the human population, providing better biological insights into the neurocognitive decline. If proven successful, these biomarkers can be used in routine clinical practice for early intervention to improve neurocognitive function in patients receiving radiation (even for other histology or other patients receiving radiation like brain metastasis).",[27,294,295,296],"Medulloblastoma","Glioma","Ependymoma",[298,299,300,301,302],"Brain Tumor","Radiotherapy","Proton Beam Therapy","Neuro-cognition","Bio-markers","2025-04-08",{"date":305,"type":40},"2025-04-11",{"date":307,"type":40},"2025-02-11",{"date":309,"type":20},"2032-02",{"name":223,"class":96},{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":21,"phases":320,"briefSummary":321,"conditions":322,"keywords":327,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":197},"100584310","early-phase-1-lipid-mediators--cancer-montelukast-spm-and-almonds-100584310","NCT06887673","Lipid Mediators & Cancer: Montelukast, SPM, and Almonds","Exploring the Impact of Montelukast, SPM, and\u002For Almond\u002FAlmond Oil Supplementation on Lipid Mediator Biosynthesis in Colorectal, Sarcomas, Brain Tumors, Endometrial, and Ovarian Cancer: A Pilot Study","Inclusion Criteria:\n\n1. Newly diagnosed individuals with stages I-IV colorectal or ovarian cancer, grade 1 and 2 endometrial cancer, as well as those with brain tumors or sarcoma.\n2. Participants scheduled for surgical intervention at least two (2) weeks from the day of enrollment.\n3. Patients must be able to understand and willing to sign a written informed consent document for both this study and the University of South Florida (USF)\u002F Tampa General Hospital (TGH) Biorepository study (STUDY000356).\n4. Age 18 or older.\n\nExclusion Criteria:\n\n1. Inability to give consent due to a mental condition that makes the participant unable to understand the study's nature, scope, and possible consequences.\n2. Participants who are unlikely to adhere to the protocol as determined by the study investigator.\n3. Allergy to fish, seafood, aspirin, NSAIDs, montelukast, or nuts\n4. Participants with a history of asthma or chronic obstructive pulmonary disease (COPD).\n5. Patients with a history of phenylketonuria (PKU).\n6. Participants with a history of a psychiatric illness (e.g., major depression, anxiety disorder, bipolar disorder, obsessive-compulsive disorder, etc.).\n7. Surgical intervention scheduled more than eight (8) weeks from the initial enrollment day.\n8. No evidence of a discrete mass on endoscopy or radiologic imaging\n9. Concomitant existence of other malignancies\n10. Uncontrolled hypertension or diabetes mellitus\n11. Chronic Liver Disease or cirrhosis\n12. Liver function impairment or persisting elevations (confirmed by retest) of alanine aminotransferase (ALT), aspartate aminotransferase (AST), or direct bilirubin greater than 2x the upper limit of the normal range (ULN)\n13. Bleeding conditions such as disorders of platelet function, idiopathic thrombocytopenia purpura (ITP), thrombotic thrombocytopenic purpura (TTP), hemophilia or any clotting factor deficiency, von Willebrand disease or Glanzmann disease among other\n14. Use of antiplatelet or anticoagulant medications, including aspirin, clopidogrel, warfarin, direct oral anticoagulants (DOACs), and heparin, among others\n15. Persistent significant or severe infection, either acute or chronic\n16. Participants with significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia (confirmed by retest):\n\n    1. Hematocrit \\\u003C 35% and\u002For\n    2. Absolute white blood cell count \\\u003C 3000 cells\u002Fmm3 (μL) and\u002For\n    3. Platelet count \\\u003C 150 000 cells\u002Fmm3 (μL) and\u002For\n    4. Absolute neutrophil ≤ 1500 cells\u002Fmm3 (μL)\n17. Chronic use of immunosuppressive medications\n18. History of organ transplantation\n19. Emergency surgery\n20. Pregnant or breast-feeding women or those who plan to become pregnant during the study.\n21. Women of childbearing potential who are not protected by effective contraceptive methods of birth control and\u002For are unwilling or unable to be tested for pregnancy.\n22. Prisoners\n23. Participants who have received treatment with leukotriene inhibitors, taken omega-3 supplements, or eaten almonds within the last 4 weeks.\n24. Prior use of any investigational drug in the preceding six (6) months\n25. Participants who, after being enrolled in this study and assigned a particular study treatment, consume products involved in other study cohorts other than what they were assigned (i.e. if a patient is assigned to take SPMs as their study treatment but during the course of the study also is consuming daily almonds)\n26. Participants who are unable to swallow oral medication or chew almonds.\n27. Participants who have already started neoadjuvant therapies for their cancer diagnosis",{"count":319,"type":20},56,[107],"The purpose of this study is to create a prospective investigation to examine the effects of montelukast, almonds\u002Falmond oil, and specialized pro-resolving mediators (SPMs) on lipid profiles and tumor-associated macrophages (TAMs) in cancer patients (colorectal cancer, sarcoma, brain tumors, endometrial cancer, and ovarian cancer). The focus will be on assessing changes in lipid mediator concentrations, TAM reprogramming, and immune cell function in treated versus untreated patients. It is hypothesized that montelukast will reduce the pro-inflammatory effects of leukotriene B4 (LTB4), while SPMs and almonds\u002Falmond oil will shift the balance toward pro-resolving mediators, enhancing anti-inflammatory and immune-stimulatory responses and reprogramming TAMs.",[323,324,27,325,326],"Colorectal Cancer","Sarcoma","Endometrial Cancer","Ovarian Cancer",[328,329,330,331,332,333,334],"Montelukast","Almonds\u002FAlmond oil","Specialized pro-resolving mediators","Tumor-associated macrophages","Lipid mediators","Colorectal cancer","Inflammation","2025-03-14",{"date":337,"type":40},"2025-03-20",{"date":339,"type":20},"2025-03",{"date":341,"type":20},"2026-03",{"name":343,"class":96},"University of South Florida",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":21,"phases":353,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":48},"100573154","phase-1-study-of-mt027-in-patients-with-brain-meninges-and-spinal-cord-metastatic-solid-tumors-100573154","NCT06742593","Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors","A Single-arm, Dose-escalating Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetic , and Efficacy of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Voluntarily participate in this study and provide a signed and dated written informed consent form prior to any study-specific procedures, sampling or analyses.\n2. Be aged 18 years or older, with no limitation on gender.\n3. Have a definite diagnosis of malignant tumor confirmed by pathology and\u002For histology (and provide complete pathological report information), and have been verified by biopsy, cytology, imaging examinations, etc. or have had previous confirmation of brain, meninges, spinal cord metastases, including lung cancer, breast cancer, colorectal cancer, melanoma, renal cell carcinoma, etc. Other solid tumor CNS metastases without standard treatment as judged by the investigator can also be considered for enrollment.\n4. The expected survival period is at least 3 months.\n5. The Karnofsky Performance Scale (KPS) score is ≥ 70 points. -\n\nExclusion Criteria:\n\n1. Known to be allergic to the investigational drug or its excipient components;\n2. Those with central nervous system metastases of hematological malignancies (such as lymphoma, leukemia, etc.);\n3. Those with metastases in the brainstem and high cervical spinal cord, including the midbrain, pons, medulla oblongata and C1\u002F2 cervical spinal cord segments;\n4. Those with severe insufficiency of heart, lung, liver and kidney functions; cardiac function: grade III or above according to the New York Heart Association (NYHA) criteria; liver function: grade C or above according to the Child-Pugh grading criteria; renal function: chronic kidney disease (CKD) stage 4 or above; renal insufficiency stage III or above; pulmonary function: severe respiratory failure symptoms involving other organs;\n5. Pregnant or lactating women;\n6. Those who are considered by the investigator to be unsuitable for participating in this clinical study due to any clinical or laboratory examination abnormalities or other reasons.",{"count":352,"type":20},12,[354],"PHASE1","MT027 is an off-the-shelf, allogeneic chimeric antigen receptor T cell (UCAR-T) injection prepared from healthy donor T cells targeting B7-H3. It is a next-generation, ready-to-use CAR-T product that can be used immediately and promptly for patients to solve the problem of unmet medical needs for a large number of patients who have a demand for CAR-T therapy but cannot receive it due to the common reasons of long production cycle, insufficient production capacity, and incompatibility of patients' T cells with the production conditions. In addition, the expected medical cost of allogeneic CAR-T cells is significantly lower, which can greatly alleviate the economic burden on patients.\n\nMT027 is prepared by expressing a chimeric antigen receptor (CAR) targeting B7H3 on gene-edited T cells through gene modification technology. MT027 products targeting the B7H3 target developed by Moxing Biotech avoid the potential graft-versus-host disease (GvHD) and host anti-graft reaction (HvGR) caused by the interaction between exogenous T cells and the patient's immune system, and have shown good safety and efficacy in recurrent high-grade glioma in the initial phase.",[261,357,27],"Brain and Central Nervous System Tumors","2024-12-17",{"date":360,"type":40},"2024-12-19",{"date":362,"type":20},"2025-01-01",{"date":364,"type":20},"2026-12-30",{"name":366,"class":47},"Suzhou Maximum Bio-tech Co., Ltd.",{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":21,"phases":376,"briefSummary":377,"conditions":378,"keywords":379,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":197},"100272328","comparison-of-proton-and-photon-radiotherapy-of-brain-tumors-protochoice-hirn-100272328","NCT02824731","Comparison of Proton and Photon Radiotherapy of Brain Tumors (ProtoChoice-Hirn)","Comparison of Proton and Photon Radiotherapy of Brain Tumors: Efficiency and Side Effects in Clinical Standard Doses","Inclusion Criteria:\n\n* primary brain tumor: gliomas (low or high grade), intracerebral meningiomas, pituitary adenomas, craniopharyngioma and other rare brain tumors or\n* brain tumor recurrence without pre-irradiation or\n* brain tumor recurrence with pre-irradiation \\> 40 Gy in the overlap region with the recurrence region\n* indication for radiotherapy or radiochemotherapy\n* Both proton and photon therapy are possible from a medical point of view (that is no standard indication for protons or standard indication for example one-time stereotaxy\n* age \\>= 18 years\n* general condition ECOG ≤ 2, outpatient basis possible\n* indication for high dose (except group 4) radiotherapy or radiochemotherapy\n* capacity to consent and present written informed consent\n\nExclusion Criteria:\n\n* lack of capacity to consent or lack of written consent\n* cerebral lymphomas\n* brain metastases\n* very small tumors (for example acoustic neuromas, very small recurrences) for this is a proton therapy from a medical point of view no alternative to a stereotactic radiotherapy\n* inability to MRI planning (eg. contraindications to performing MRI)\n* lack of compliance of the patient\n* lack of or limited possibility of a reproducible storage (eg by severe restriction of mobility of the patient)\n* missing or limited possibility of regular follow-up visits in accordance with the study protocol",{"count":375,"type":20},555,[23],"This protocol compares the toxicity of radiotherapy or radiochemotherapy applied with different radiation modalities - protons or photons. Patients with different kinds of brain tumours and foreseen high-dose radiotherapy can be included. The hypothesis of the trial is that the rate of chronic toxicity 1 year after the end of radiotherapy is 15% lower after proton compared to photon treatment.",[27],[30,380,381],"proton radiotherapy","photon radiotherapy","2024-12-11",{"date":384,"type":40},"2024-12-16",{"date":386,"type":40},"2016-07",{"date":388,"type":20},"2029-10",{"name":390,"class":96},"Technische Universität Dresden"]